Innoventric
Transcatheter Solution for Tricuspid Regurgitation
Company Overview
Snapshot
Founded in February 2016 by Amir Danino, David Planer, and Rafi Benary, Innoventric operates with 11–50 employees. The company has raised $42.5M across 4 funding rounds from 6 investors. In October 2024, Innoventric secured a B Round of funding, led by RA Capital Management.
Business overview
Innoventric is a structural heart medical device company focused on developing percutaneous solutions for tricuspid regurgitation and right heart disease. The company's core product is an easily deployable percutaneous functional tricuspid valve replacement, Trillium, which utilizes cross-caval anchoring and an innovative multi-valve design for long-lasting blood flow regulation. Innoventric aims to significantly improve the quality of life and lifespan for patients with structural heart disease, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers in geomarkets such as Europe and the United States.
Strategic signal
In October 2024, Innoventric secured a B Round of funding, led by RA Capital Management. This investment highlights continued investor confidence in the company's innovative transcatheter solutions for tricuspid regurgitation, signaling strong potential for advancing medical device technology and reducing the need for traditional surgical valve replacement.
Log in to access full profile ›Company Intelligence Q&A
- What is Innoventric's primary focus?
- Innoventric is primarily engaged in the development of percutaneous solutions for tricuspid regurgitation and right heart disease, aiming to improve the quality of life for patients with structural heart disease.
- When was Innoventric's most recent funding round?
- In October 2024, Innoventric secured a B Round of funding, led by RA Capital Management.
- Which product is Innoventric currently developing?
- Innoventric is developing Trillium, an easily deployable percutaneous functional tricuspid valve replacement that uses cross-caval anchoring and a multi-valve design.
- When did Innoventric secure its Series A investment?
- In November 2021, Innoventric secured a Series A investment from investors including JG Investment.
- Has Innoventric received any grants?
- In November 2021, Innoventric received a grant from the EU Horizon 2020 program.